Global Therapeutic Monoclonal Antibodies Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

December 2023 | 133 pages | ID: GE3229BE30B4EN
GlobalInfoResearch

Abstracts

According to our (Global Info Research) latest study, the global Therapeutic Monoclonal Antibodies Drug market size was valued at USD 167110 million in 2022 and is forecast to a readjusted size of USD 336740 million by 2029 with a CAGR of 10.5% during review period.

Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.

The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.

The Global Info Research report includes an overview of the development of the Therapeutic Monoclonal Antibodies Drug industry chain, the market status of Immune Diseases (Mouse-derived Antibodies, Chimeric Antibodies), Cancer (Mouse-derived Antibodies, Chimeric Antibodies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Therapeutic Monoclonal Antibodies Drug.

Regionally, the report analyzes the Therapeutic Monoclonal Antibodies Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Therapeutic Monoclonal Antibodies Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Therapeutic Monoclonal Antibodies Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Therapeutic Monoclonal Antibodies Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Tons), revenue generated, and market share of different by Type (e.g., Mouse-derived Antibodies, Chimeric Antibodies).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Therapeutic Monoclonal Antibodies Drug market.

Regional Analysis: The report involves examining the Therapeutic Monoclonal Antibodies Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Therapeutic Monoclonal Antibodies Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Therapeutic Monoclonal Antibodies Drug:

Company Analysis: Report covers individual Therapeutic Monoclonal Antibodies Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Therapeutic Monoclonal Antibodies Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Immune Diseases, Cancer).

Technology Analysis: Report covers specific technologies relevant to Therapeutic Monoclonal Antibodies Drug. It assesses the current state, advancements, and potential future developments in Therapeutic Monoclonal Antibodies Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Therapeutic Monoclonal Antibodies Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Therapeutic Monoclonal Antibodies Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type

• Mouse-derived Antibodies
• Chimeric Antibodies
• Humanized Antibodies

Market segment by Application

• Immune Diseases
• Cancer
• Other

Major players covered

• AbbVie
• Johnson & Johnson
• Novartis
• Gilead Sciences
• Roche
• Bristol-Myers Squibb
• Amgen
• AstraZeneca
• Merck & Co
• Takeda
• Merck KGaA
• Seagen
• Eli Lilly
• Ono Pharmaceutical
• Pfizer
• Regeneron
• Innovent
• Hengrui Medicine

Market segment by region, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
• Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
• South America (Brazil, Argentina, Colombia, and Rest of South America)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Therapeutic Monoclonal Antibodies Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Therapeutic Monoclonal Antibodies Drug, with price, sales, revenue and global market share of Therapeutic Monoclonal Antibodies Drug from 2018 to 2023.

Chapter 3, the Therapeutic Monoclonal Antibodies Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Therapeutic Monoclonal Antibodies Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Therapeutic Monoclonal Antibodies Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Therapeutic Monoclonal Antibodies Drug.

Chapter 14 and 15, to describe Therapeutic Monoclonal Antibodies Drug sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope of Therapeutic Monoclonal Antibodies Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
  1.3.1 Overview: Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
  1.3.2 Mouse-derived Antibodies
  1.3.3 Chimeric Antibodies
  1.3.4 Humanized Antibodies
1.4 Market Analysis by Application
  1.4.1 Overview: Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
  1.4.2 Immune Diseases
  1.4.3 Cancer
  1.4.4 Other
1.5 Global Therapeutic Monoclonal Antibodies Drug Market Size & Forecast
  1.5.1 Global Therapeutic Monoclonal Antibodies Drug Consumption Value (2018 & 2022 & 2029)
  1.5.2 Global Therapeutic Monoclonal Antibodies Drug Sales Quantity (2018-2029)
  1.5.3 Global Therapeutic Monoclonal Antibodies Drug Average Price (2018-2029)

2 MANUFACTURERS PROFILES

2.1 AbbVie
  2.1.1 AbbVie Details
  2.1.2 AbbVie Major Business
  2.1.3 AbbVie Therapeutic Monoclonal Antibodies Drug Product and Services
  2.1.4 AbbVie Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.1.5 AbbVie Recent Developments/Updates
2.2 Johnson & Johnson
  2.2.1 Johnson & Johnson Details
  2.2.2 Johnson & Johnson Major Business
  2.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product and Services
  2.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.2.5 Johnson & Johnson Recent Developments/Updates
2.3 Novartis
  2.3.1 Novartis Details
  2.3.2 Novartis Major Business
  2.3.3 Novartis Therapeutic Monoclonal Antibodies Drug Product and Services
  2.3.4 Novartis Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.3.5 Novartis Recent Developments/Updates
2.4 Gilead Sciences
  2.4.1 Gilead Sciences Details
  2.4.2 Gilead Sciences Major Business
  2.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product and Services
  2.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.4.5 Gilead Sciences Recent Developments/Updates
2.5 Roche
  2.5.1 Roche Details
  2.5.2 Roche Major Business
  2.5.3 Roche Therapeutic Monoclonal Antibodies Drug Product and Services
  2.5.4 Roche Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.5.5 Roche Recent Developments/Updates
2.6 Bristol-Myers Squibb
  2.6.1 Bristol-Myers Squibb Details
  2.6.2 Bristol-Myers Squibb Major Business
  2.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product and Services
  2.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.6.5 Bristol-Myers Squibb Recent Developments/Updates
2.7 Amgen
  2.7.1 Amgen Details
  2.7.2 Amgen Major Business
  2.7.3 Amgen Therapeutic Monoclonal Antibodies Drug Product and Services
  2.7.4 Amgen Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.7.5 Amgen Recent Developments/Updates
2.8 AstraZeneca
  2.8.1 AstraZeneca Details
  2.8.2 AstraZeneca Major Business
  2.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Drug Product and Services
  2.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.8.5 AstraZeneca Recent Developments/Updates
2.9 Merck & Co
  2.9.1 Merck & Co Details
  2.9.2 Merck & Co Major Business
  2.9.3 Merck & Co Therapeutic Monoclonal Antibodies Drug Product and Services
  2.9.4 Merck & Co Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.9.5 Merck & Co Recent Developments/Updates
2.10 Takeda
  2.10.1 Takeda Details
  2.10.2 Takeda Major Business
  2.10.3 Takeda Therapeutic Monoclonal Antibodies Drug Product and Services
  2.10.4 Takeda Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.10.5 Takeda Recent Developments/Updates
2.11 Merck KGaA
  2.11.1 Merck KGaA Details
  2.11.2 Merck KGaA Major Business
  2.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Drug Product and Services
  2.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.11.5 Merck KGaA Recent Developments/Updates
2.12 Seagen
  2.12.1 Seagen Details
  2.12.2 Seagen Major Business
  2.12.3 Seagen Therapeutic Monoclonal Antibodies Drug Product and Services
  2.12.4 Seagen Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.12.5 Seagen Recent Developments/Updates
2.13 Eli Lilly
  2.13.1 Eli Lilly Details
  2.13.2 Eli Lilly Major Business
  2.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Drug Product and Services
  2.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.13.5 Eli Lilly Recent Developments/Updates
2.14 Ono Pharmaceutical
  2.14.1 Ono Pharmaceutical Details
  2.14.2 Ono Pharmaceutical Major Business
  2.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product and Services
  2.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.14.5 Ono Pharmaceutical Recent Developments/Updates
2.15 Pfizer
  2.15.1 Pfizer Details
  2.15.2 Pfizer Major Business
  2.15.3 Pfizer Therapeutic Monoclonal Antibodies Drug Product and Services
  2.15.4 Pfizer Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.15.5 Pfizer Recent Developments/Updates
2.16 Regeneron
  2.16.1 Regeneron Details
  2.16.2 Regeneron Major Business
  2.16.3 Regeneron Therapeutic Monoclonal Antibodies Drug Product and Services
  2.16.4 Regeneron Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.16.5 Regeneron Recent Developments/Updates
2.17 Innovent
  2.17.1 Innovent Details
  2.17.2 Innovent Major Business
  2.17.3 Innovent Therapeutic Monoclonal Antibodies Drug Product and Services
  2.17.4 Innovent Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.17.5 Innovent Recent Developments/Updates
2.18 Hengrui Medicine
  2.18.1 Hengrui Medicine Details
  2.18.2 Hengrui Medicine Major Business
  2.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product and Services
  2.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
  2.18.5 Hengrui Medicine Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: THERAPEUTIC MONOCLONAL ANTIBODIES DRUG BY MANUFACTURER

3.1 Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Therapeutic Monoclonal Antibodies Drug Revenue by Manufacturer (2018-2023)
3.3 Global Therapeutic Monoclonal Antibodies Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
  3.4.1 Producer Shipments of Therapeutic Monoclonal Antibodies Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
  3.4.2 Top 3 Therapeutic Monoclonal Antibodies Drug Manufacturer Market Share in 2022
  3.4.2 Top 6 Therapeutic Monoclonal Antibodies Drug Manufacturer Market Share in 2022
3.5 Therapeutic Monoclonal Antibodies Drug Market: Overall Company Footprint Analysis
  3.5.1 Therapeutic Monoclonal Antibodies Drug Market: Region Footprint
  3.5.2 Therapeutic Monoclonal Antibodies Drug Market: Company Product Type Footprint
  3.5.3 Therapeutic Monoclonal Antibodies Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Therapeutic Monoclonal Antibodies Drug Market Size by Region
  4.1.1 Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2018-2029)
  4.1.2 Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2018-2029)
  4.1.3 Global Therapeutic Monoclonal Antibodies Drug Average Price by Region (2018-2029)
4.2 North America Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029)
4.3 Europe Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029)
4.5 South America Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

5.1 Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
5.2 Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type (2018-2029)
5.3 Global Therapeutic Monoclonal Antibodies Drug Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
6.2 Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application (2018-2029)
6.3 Global Therapeutic Monoclonal Antibodies Drug Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
7.2 North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
7.3 North America Therapeutic Monoclonal Antibodies Drug Market Size by Country
  7.3.1 North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2029)
  7.3.2 North America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2029)
  7.3.3 United States Market Size and Forecast (2018-2029)
  7.3.4 Canada Market Size and Forecast (2018-2029)
  7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
8.2 Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
8.3 Europe Therapeutic Monoclonal Antibodies Drug Market Size by Country
  8.3.1 Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2029)
  8.3.2 Europe Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2029)
  8.3.3 Germany Market Size and Forecast (2018-2029)
  8.3.4 France Market Size and Forecast (2018-2029)
  8.3.5 United Kingdom Market Size and Forecast (2018-2029)
  8.3.6 Russia Market Size and Forecast (2018-2029)
  8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Market Size by Region
  9.3.1 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2018-2029)
  9.3.2 Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2018-2029)
  9.3.3 China Market Size and Forecast (2018-2029)
  9.3.4 Japan Market Size and Forecast (2018-2029)
  9.3.5 Korea Market Size and Forecast (2018-2029)
  9.3.6 India Market Size and Forecast (2018-2029)
  9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
  9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
10.2 South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
10.3 South America Therapeutic Monoclonal Antibodies Drug Market Size by Country
  10.3.1 South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2029)
  10.3.2 South America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2029)
  10.3.3 Brazil Market Size and Forecast (2018-2029)
  10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Market Size by Country
  11.3.1 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2029)
  11.3.2 Middle East & Africa Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2029)
  11.3.3 Turkey Market Size and Forecast (2018-2029)
  11.3.4 Egypt Market Size and Forecast (2018-2029)
  11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
  11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Therapeutic Monoclonal Antibodies Drug Market Drivers
12.2 Therapeutic Monoclonal Antibodies Drug Market Restraints
12.3 Therapeutic Monoclonal Antibodies Drug Trends Analysis
12.4 Porters Five Forces Analysis
  12.4.1 Threat of New Entrants
  12.4.2 Bargaining Power of Suppliers
  12.4.3 Bargaining Power of Buyers
  12.4.4 Threat of Substitutes
  12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Therapeutic Monoclonal Antibodies Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Therapeutic Monoclonal Antibodies Drug
13.3 Therapeutic Monoclonal Antibodies Drug Production Process
13.4 Therapeutic Monoclonal Antibodies Drug Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel
  14.1.1 Direct to End-User
  14.1.2 Distributors
14.2 Therapeutic Monoclonal Antibodies Drug Typical Distributors
14.3 Therapeutic Monoclonal Antibodies Drug Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION


16 APPENDIX

16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Therapeutic Monoclonal Antibodies Drug Product and Services
Table 6. AbbVie Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Recent Developments/Updates
Table 8. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 9. Johnson & Johnson Major Business
Table 10. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Product and Services
Table 11. Johnson & Johnson Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Johnson & Johnson Recent Developments/Updates
Table 13. Novartis Basic Information, Manufacturing Base and Competitors
Table 14. Novartis Major Business
Table 15. Novartis Therapeutic Monoclonal Antibodies Drug Product and Services
Table 16. Novartis Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis Recent Developments/Updates
Table 18. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 19. Gilead Sciences Major Business
Table 20. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Product and Services
Table 21. Gilead Sciences Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Gilead Sciences Recent Developments/Updates
Table 23. Roche Basic Information, Manufacturing Base and Competitors
Table 24. Roche Major Business
Table 25. Roche Therapeutic Monoclonal Antibodies Drug Product and Services
Table 26. Roche Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Roche Recent Developments/Updates
Table 28. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 29. Bristol-Myers Squibb Major Business
Table 30. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Product and Services
Table 31. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Bristol-Myers Squibb Recent Developments/Updates
Table 33. Amgen Basic Information, Manufacturing Base and Competitors
Table 34. Amgen Major Business
Table 35. Amgen Therapeutic Monoclonal Antibodies Drug Product and Services
Table 36. Amgen Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Amgen Recent Developments/Updates
Table 38. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 39. AstraZeneca Major Business
Table 40. AstraZeneca Therapeutic Monoclonal Antibodies Drug Product and Services
Table 41. AstraZeneca Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AstraZeneca Recent Developments/Updates
Table 43. Merck & Co Basic Information, Manufacturing Base and Competitors
Table 44. Merck & Co Major Business
Table 45. Merck & Co Therapeutic Monoclonal Antibodies Drug Product and Services
Table 46. Merck & Co Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Merck & Co Recent Developments/Updates
Table 48. Takeda Basic Information, Manufacturing Base and Competitors
Table 49. Takeda Major Business
Table 50. Takeda Therapeutic Monoclonal Antibodies Drug Product and Services
Table 51. Takeda Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Takeda Recent Developments/Updates
Table 53. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 54. Merck KGaA Major Business
Table 55. Merck KGaA Therapeutic Monoclonal Antibodies Drug Product and Services
Table 56. Merck KGaA Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Merck KGaA Recent Developments/Updates
Table 58. Seagen Basic Information, Manufacturing Base and Competitors
Table 59. Seagen Major Business
Table 60. Seagen Therapeutic Monoclonal Antibodies Drug Product and Services
Table 61. Seagen Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Seagen Recent Developments/Updates
Table 63. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 64. Eli Lilly Major Business
Table 65. Eli Lilly Therapeutic Monoclonal Antibodies Drug Product and Services
Table 66. Eli Lilly Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Eli Lilly Recent Developments/Updates
Table 68. Ono Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 69. Ono Pharmaceutical Major Business
Table 70. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Product and Services
Table 71. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Ono Pharmaceutical Recent Developments/Updates
Table 73. Pfizer Basic Information, Manufacturing Base and Competitors
Table 74. Pfizer Major Business
Table 75. Pfizer Therapeutic Monoclonal Antibodies Drug Product and Services
Table 76. Pfizer Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Pfizer Recent Developments/Updates
Table 78. Regeneron Basic Information, Manufacturing Base and Competitors
Table 79. Regeneron Major Business
Table 80. Regeneron Therapeutic Monoclonal Antibodies Drug Product and Services
Table 81. Regeneron Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Regeneron Recent Developments/Updates
Table 83. Innovent Basic Information, Manufacturing Base and Competitors
Table 84. Innovent Major Business
Table 85. Innovent Therapeutic Monoclonal Antibodies Drug Product and Services
Table 86. Innovent Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Innovent Recent Developments/Updates
Table 88. Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 89. Hengrui Medicine Major Business
Table 90. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Product and Services
Table 91. Hengrui Medicine Therapeutic Monoclonal Antibodies Drug Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Hengrui Medicine Recent Developments/Updates
Table 93. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Manufacturer (2018-2023) & (Tons)
Table 94. Global Therapeutic Monoclonal Antibodies Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 95. Global Therapeutic Monoclonal Antibodies Drug Average Price by Manufacturer (2018-2023) & (US$/Ton)
Table 96. Market Position of Manufacturers in Therapeutic Monoclonal Antibodies Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 97. Head Office and Therapeutic Monoclonal Antibodies Drug Production Site of Key Manufacturer
Table 98. Therapeutic Monoclonal Antibodies Drug Market: Company Product Type Footprint
Table 99. Therapeutic Monoclonal Antibodies Drug Market: Company Product Application Footprint
Table 100. Therapeutic Monoclonal Antibodies Drug New Market Entrants and Barriers to Market Entry
Table 101. Therapeutic Monoclonal Antibodies Drug Mergers, Acquisition, Agreements, and Collaborations
Table 102. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2018-2023) & (Tons)
Table 103. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2024-2029) & (Tons)
Table 104. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 105. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 106. Global Therapeutic Monoclonal Antibodies Drug Average Price by Region (2018-2023) & (US$/Ton)
Table 107. Global Therapeutic Monoclonal Antibodies Drug Average Price by Region (2024-2029) & (US$/Ton)
Table 108. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 109. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 110. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 111. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 112. Global Therapeutic Monoclonal Antibodies Drug Average Price by Type (2018-2023) & (US$/Ton)
Table 113. Global Therapeutic Monoclonal Antibodies Drug Average Price by Type (2024-2029) & (US$/Ton)
Table 114. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 115. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 116. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 117. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 118. Global Therapeutic Monoclonal Antibodies Drug Average Price by Application (2018-2023) & (US$/Ton)
Table 119. Global Therapeutic Monoclonal Antibodies Drug Average Price by Application (2024-2029) & (US$/Ton)
Table 120. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 121. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 122. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 123. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 124. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2023) & (Tons)
Table 125. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2024-2029) & (Tons)
Table 126. North America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 127. North America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 128. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 129. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 130. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 131. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 132. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2023) & (Tons)
Table 133. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2024-2029) & (Tons)
Table 134. Europe Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 135. Europe Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 136. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 137. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 138. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 139. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 140. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2018-2023) & (Tons)
Table 141. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2024-2029) & (Tons)
Table 142. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 143. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 144. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 145. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 146. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 147. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 148. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2018-2023) & (Tons)
Table 149. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity by Country (2024-2029) & (Tons)
Table 150. South America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 151. South America Therapeutic Monoclonal Antibodies Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 152. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2018-2023) & (Tons)
Table 153. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Type (2024-2029) & (Tons)
Table 154. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2018-2023) & (Tons)
Table 155. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Application (2024-2029) & (Tons)
Table 156. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2018-2023) & (Tons)
Table 157. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity by Region (2024-2029) & (Tons)
Table 158. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 159. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 160. Therapeutic Monoclonal Antibodies Drug Raw Material
Table 161. Key Manufacturers of Therapeutic Monoclonal Antibodies Drug Raw Materials
Table 162. Therapeutic Monoclonal Antibodies Drug Typical Distributors
Table 163. Therapeutic Monoclonal Antibodies Drug Typical Customers

LIST OF FIGURE
s
Figure 1. Therapeutic Monoclonal Antibodies Drug Picture
Figure 2. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Type in 2022
Figure 4. Mouse-derived Antibodies Examples
Figure 5. Chimeric Antibodies Examples
Figure 6. Humanized Antibodies Examples
Figure 7. Global Therapeutic Monoclonal Antibodies Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Application in 2022
Figure 9. Immune Diseases Examples
Figure 10. Cancer Examples
Figure 11. Other Examples
Figure 12. Global Therapeutic Monoclonal Antibodies Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Therapeutic Monoclonal Antibodies Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity (2018-2029) & (Tons)
Figure 15. Global Therapeutic Monoclonal Antibodies Drug Average Price (2018-2029) & (US$/Ton)
Figure 16. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Therapeutic Monoclonal Antibodies Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Therapeutic Monoclonal Antibodies Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Therapeutic Monoclonal Antibodies Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Therapeutic Monoclonal Antibodies Drug Average Price by Type (2018-2029) & (US$/Ton)
Figure 31. Global Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Therapeutic Monoclonal Antibodies Drug Average Price by Application (2018-2029) & (US$/Ton)
Figure 34. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Region (2018-2029)
Figure 54. China Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Therapeutic Monoclonal Antibodies Drug Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Therapeutic Monoclonal Antibodies Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Therapeutic Monoclonal Antibodies Drug Market Drivers
Figure 75. Therapeutic Monoclonal Antibodies Drug Market Restraints
Figure 76. Therapeutic Monoclonal Antibodies Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Therapeutic Monoclonal Antibodies Drug in 2022
Figure 79. Manufacturing Process Analysis of Therapeutic Monoclonal Antibodies Drug
Figure 80. Therapeutic Monoclonal Antibodies Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source